INBX

Inhibrx Inc.

Price

$83.69

return (12m)

262.62%

p/e

-10.29

p/bv

-63.69

DIVIDEND YIELD

0.00%

INBX price

Inhibrx

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment INBX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-11.73%

3 months

-35.95%

1 year

262.62%

2 years

509.56%

5 years

185.91%

10 years

0.00%

Fundamentals INBX

Valuation

P/E

-10.29

Sector -4.03

Industry -4.03

P/BV

-63.69

Sector 2.05

Industry 2.05

P/Revenue (PSR)

1,030.77

Sector -4.26

Industry -4.26

EV/EBITDA

-46.03

Sector -238.32

Industry -238.32

EV/EBIT

-45.22

Sector -670.55

Industry -670.55

P/EBITDA

-11.67

Sector -4.23

Industry -4.23

P/EBIT

-11.44

Sector -4.29

Industry -4.29

P/Total Assets

7.28

Sector 1.45

Industry 1.45

P/Ativo Circ. Liq.

-39.81

Sector -11.51

Industry -11.51

P/Cap.Giro

9.25

Sector -11.45

Industry -11.45

EPS

-8.14

Sector -2.20

Industry -2.20

BVPS

-1.32

Sector 1.95

Industry 1.95

Efficiency

Gross Margin

100.00%

Sector 36.28%

Industry 36.28%

EBITDA Margin

Sector -16,822.56%

Industry -16,822.56%

EBIT Margin

Sector -4,238,732.42%

Industry -4,238,732.42%

Operating Margin

-100.00%

Sector -38.78%

Industry -38.78%

Net Profit Margins

-100.00%

Sector -39.92%

Industry -39.92%

Giro Ativos

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

618.73%

Sector -65.93%

Industry -65.93%

ROA

-70.76%

Sector -66.10%

Industry -66.10%

ROIC

-607.93%

Sector -2,918.81%

Industry -2,918.81%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.46

Sector 2.91

Industry 2.91

Dívida Líquida/EBITDA

-0.45

Sector -13,526,126.12

Industry -13,526,126.12

Dívida Líquida/EBIT

-0.45

Sector -3.66

Industry -3.66

Dívida Líquida/Patrimônio

-0.63

Sector -1.10

Industry -1.10

Dívida Bruta/Patrimônio

-8.32

Sector -0.10

Industry -0.10

Equity/Assets

-0.11

Sector 0.42

Industry 0.42

Liabilities/Assets

1.11

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals INBX

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
INBX	-10.29	-63.69	618.73%	0.00%	$1.34 B	-100.00%
JNJ	30.06	7.44	24.76%	1.99%	$632.34 B	21.48%
PFE	18.39	1.52	8.29%	7.11%	$137.74 B	11.83%
ABBV	126.05	-69.30	-54.98%	2.60%	$458.19 B	5.79%
NVO	11.48	6.93	60.40%	3.79%	$217.68 B	37.15%
MRK	36.33	7.07	19.45%	2.56%	$324.61 B	13.59%
AZN	25.14	5.51	21.93%	1.90%	$261.15 B	17.19%
GILD	17.54	6.90	39.33%	2.47%	$161.64 B	30.99%
BMY	17.28	6.25	36.19%	4.05%	$125.69 B	15.01%
ZTS	11.99	9.80	81.75%	2.74%	$31.69 B	27.79%
REGN	15.66	2.20	14.08%	0.55%	$69.27 B	29.65%
HALO	27.62	43.86	158.82%	0.00%	$9.63 B	23.13%
AMGN	26.05	22.11	84.87%	2.60%	$203.18 B	20.96%
MCK	21.59	-123.30	-570.98%	0.39%	$102.83 B	1.18%
VRTX	28.04	6.28	22.41%	0.00%	$121.66 B	35.51%
CAH	34.58	-20.13	-58.20%	0.89%	$53.78 B	0.62%
HRMY	14.10	2.26	16.00%	0.00%	$2.05 B	16.20%
BIIB	21.68	1.59	7.36%	0.00%	$29.75 B	13.81%
MEDP	34.42	38.99	113.29%	0.00%	$16.92 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INBX Historical Dividends

current DY: 0.00%

5-year average DY: 2.81%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	05/29/2024	06/20/2024	0.85000000

ABOUT Inhibrx

Inhibrx Inc.

Average Investor10 user rating

4.0 (4 people)

United States

9 years

Founded: 2017

2020

Time since IPO - 6 years

91

Employees

Inhibrx Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.34 billion, with shareholders equity totaling $-21.04 million.

The company employs approximately 91 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Inhibrx Inc. reported $1.30 million in revenue, generating net income of $-130.18 million.

Key financial metrics include a P/E ratio of -10.29, a price-to-book (P/B) ratio of -63.69, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INBX.

Market cap

$1.34 billion

Net worth

$-21.04 million

$-21,040,000.00

Assets

$183.97 million

$183,970,000.00

Total Shares Outstanding

16.00 million

16,000,000

Average Daily Trading Volume

$347.47 Thousand

$347,468.00

Sector

Health Care

Industry

Biotechnology

INBX

INBX revenue and profits

Financial Results INBX

DRAG THE FRAME TO SEE MORE DATA

INBX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$855.08 20,75% (12M)

P/E

21.59

0.39%

ROE

-570.98%

P/BV

-123.30

CAH - Cardinal Health

$230.27 48,08% (12M)

P/E

34.58

0.89%

ROE

-58.20%

P/BV

-20.13

JNJ - Johnson & Johnson

$267.58 63,82% (12M)

P/E

30.06

1.99%

ROE

24.76%

P/BV

7.44

MRK - Merck & Co.

$131.89 60,86% (12M)

P/E

36.33

2.56%

ROE

19.45%

P/BV

7.07

AZN - AstraZeneca

$170.63 17,35% (12M)

P/E

25.14

1.90%

ROE

21.93%

P/BV

5.51

ABBV - AbbVie

$260.03 42,23% (12M)

P/E

126.05

2.60%

ROE

-54.98%

P/BV

-69.30

NVO - Novo Nordisk

$49.48 --3,83% (12M)

P/E

11.48

3.79%

ROE

60.40%

P/BV

6.93

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$855.08 20,75% (12 M)

P/L

21.59

0.39%

ROE

-570.98%

P/VP

-123.30

CAH - Cardinal Health

$230.27 48,08% (12 M)

P/L

34.58

0.89%

ROE

-58.20%

P/VP

-20.13

JNJ - Johnson & Johnson

$267.58 63,82% (12 M)

P/L

30.06

1.99%

ROE

24.76%

P/VP

7.44

MRK - Merck & Co.

$131.89 60,86% (12 M)

P/L

36.33

2.56%

ROE

19.45%

P/VP

7.07

AZN - AstraZeneca

$170.63 17,35% (12 M)

P/L

25.14

1.90%

ROE

21.93%

P/VP

5.51

ABBV - AbbVie

$260.03 42,23% (12 M)

P/L

126.05

2.60%

ROE

-54.98%

P/VP

-69.30

NVO - Novo Nordisk

$49.48 --3,83% (12 M)

P/L

11.48

3.79%

ROE

60.40%

P/VP

6.93

Frequently Asked Questions

What is the price of Inhibrx (INBX) today?

A cotação de Inhibrx (INBX) hoje está em US$ 83.69, com uma variação de 262.62% em relação ao último ano. A cotação de Inhibrx (INBX) iniciou o ano negociando na casa dos US$ 79.00 e hoje está em US$ 83.69. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Inhibrx (INBX) e dados de ações do Ibovespa e mercados internacionais.

Quando Inhibrx (INBX) paga dividendos?

Inhibrx (INBX) não distribuiu dividendos no último ano.

Is Inhibrx (INBX) a good investment?

Atualmente, Inhibrx (INBX) está cotada a US$ 83.69, com um P/L de -10.29, representando um desvio de -426% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 262.62 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 262.62%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Inhibrx (INBX) stock?

Investir em ações de Inhibrx (INBX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Inhibrx (INBX) yield today?

A rentabilidade de Inhibrx (INBX) foi de -11.73% no último mês, 262.62% no último ano e 185.91% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Inhibrx (INBX) hoje, o investimento total seria de US$ 8,369.25, com base na cotação atual de US$ 83.69.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 30,348.57
Em 5 anos: US$ 23,928.52
Em 10 anos: US$ 8,369.25

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

INBX

Inhibrx Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment INBX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

current DY: 0.00%

5-year average DY: 2.81%

type

Ex - Dividend Date

payment date

value

ABOUT Inhibrx

Inhibrx Inc.

United States

9 years

2020

91

Financial Results INBX

INBX cash flow

Asset, Revenue and Profit Growth - INBX

INBX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions